Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic review for a KDOQI clinical practice guideline

American Journal of Kidney Diseases

Volumn 60, Issue 5, 2012, Pages 747-769

  Slinin, Yelena ^a,b   Ishani, Areef ^a,b   Rector, Thomas ^a   Fitzgerald, Patrick ^a   MacDonald, Roderick ^a   Tacklind, James ^a,b   Rutks, Indulis ^a   Wilt, Timothy J ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

albuminuria; chronic kidney disease; Diabetes; hyperglycemia; lipid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CYANOCOBALAMIN; ENALAPRIL; FENOFIBRATE; FOLIC ACID; GEMFIBROZIL; GLICLAZIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; LOSARTAN; OLMESARTAN; PERINDOPRIL; PRAVASTATIN; PYRIDOXINE; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN;

ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ALBUMINURIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867545487     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.07.017     Document Type: Article

References (45)

1. US Renal Data System USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Am J Kidney Dis 57 1 2011 e1 e526 (suppl 1)
2. National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Kidney Diseases Am J Kidney Dis 49 suppl 2 2007 S1 S180
3. National Kidney Foundation KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update Am J Kidney Dis 60 5 2012 850 886
4. J.P.T. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions 2011 The Cochrane Collaboration Version 5.1.0 [updated March 2011]
5. Review Manager [computer program] Version 5.0 2008 The Nordic Cochrane Centre, The Cochrane Collaboration Copenhagen, the Netherlands
6. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
7. D.K. Owens, K.N. Lohr, D. Atkins AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions - Agency for Healthcare Research and Quality and the Effective Health-Care Program J Clin Epidemiol 63 5 2010 513 523
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group Lancet 352 9131 1998 837 853
9. W. Duckworth, C. Abraira, T. Moritz Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2 2009 129 139
10. A. Patel, S. MacMahon, J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 2008 2560 2572
11. H.C. Gerstein, M.E. Miller, R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 24 2008 2545 2559
12. F. Ismail-Beigi, T. Craven, M.A. Banerji Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 9739 2010 419 430
13. M. Shichiri, H. Kishikawa, Y. Ohkubo, N. Wake Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care 23 suppl 2 2000 B21 B29
14. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 9374 2003 2005 2016
15. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 5 2009 810 819
16. M. Tonelli, A. Keech, J. Shepherd Effect of pravastatin in people with diabetes and chronic kidney disease J Am Soc Nephrol 16 12 2005 3748 3754
17. M. Chonchol, T. Cook, J. Kjekshus, T.R. Pedersen, J. Lindenfeld Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency Am J Kidney Dis 49 2007 373 382
18. J. Shepherd, J.J. Kastelein, V. Bittner Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) Study J Am Coll Cardiol 51 15 2008 1448 1454
19. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 14 2009 1395 1407
20. C. Wanner, V. Krane, W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 2005 238 248
21. A.G. Jardine, H. Holdaas, B. Fellstrom Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study Am J Transplant 4 6 2004 988 995
22. M. Tonelli, D. Collins, S. Robins, H. Bloomfield, G.C. Curhan Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency Kidney Int 66 3 2004 1123 1130
23. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 3 2005 485 493
24. T.M. Davis, R. Ting, J.D. Best Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2 2011 280 290
25. A.A. House, M. Eliasziw, D.C. Cattran Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial JAMA 303 16 2010 1603 1609
26. J.F.E. Mann, R.E. Schmieder, M. McQueen Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 9638 2008 547 553
27. M. Mauer, B. Zinman, R. Gardiner Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 1 2009 40 51
28. H. Haller, S. Ito, J.L. Izzo Jr Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 10 2011 907 917
29. B.E. de Galan, V. Perkovic, T. Ninomiya Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 4 2009 883 892
30. A. Patel, S. MacMahon, J. Chalmers Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 9590 2007 829 840
31. J.F. Mann, R.E. Schmieder, L. Dyal Effect of telmisartan on renal outcomes: a randomized trial Ann Intern Med 151 1 2009 1 10 W11-W12
32. W.C. Cushman, G.W. Evans, R.P. Byington Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 17 2010 1575 1585
33. R. Bilous, N. Chaturvedi, A.K. Sjolie Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 1 2009 11 20 W13-W14
34. R.O. Estacio, J.R. Coll, Z.V. Tran, R.W. Schrier Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes Am J Hypertens 19 12 2006 1241 1248
35. H. Makino, M. Haneda, T. Babazono Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of the Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study Hypertens Res 31 4 2008 657 664
36. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
37. D.M. Nathan, P.A. Cleary, J.Y. Backlund Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 25 2005 2643 2653
38. DCCT/EDIC Research Group; de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 20112;365(25):2366-2376.
39. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 2004 685 696
40. P.M. Kearney, L. Blackwell, R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 9607 2008 117 125
41. C. Baigent, L. Blackwell, J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 9753 2010 1670 1681
42. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 2011 2181 2192
43. A.S. Levey, D. Cattran, A. Friedman Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 54 2 2009 205 226
44. H. Makino, M. Haneda, T. Babazono Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes Diabetes Care 30 6 2007 1577 1578
45. H. Holdaas, I. Holme, R.E. Schmieder AURORA Study Group Rosuvastatin in diabetic hemodialysis patients J Am Soc Nephrol 22 7 2011 1335 1341